Skip to content
value.today

Diceros Therapeutics, Inc.

🇺🇸 Newton, Massachusetts, USABiotechnologyFounded 2022
Total raised
$13 M
1 round on record
Latest round
$13 M
Sep 2022
First round on record
Sep 2022
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Diceros Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$13 MNo. 1$10 to $50 million

Diceros Therapeutics, Inc.: Raise no. 1, Sep 2022

Investors in this round

13 investors had bought by the notice of Aug 5, 2024: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $18 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,038,035 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen R. Seiler · Executive Officer, Director
  • Ids R. van der Weij · Director
  • Jonathan R. Fleming · Director
  • Wyatt R. Gotbetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen R. Seiler, President & CEO. Newest notice filed Aug 5, 2024 (1 amendment). Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Diceros Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).

    SEC Form D · Aug 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Diceros Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Diceros Therapeutics, Inc.
NameRoleNamed in
Stephen R. SeilerExecutive officerAug 2024
Ids R. van der WeijDirectorAug 2024
Jonathan R. FlemingDirectorAug 2024
Stephen R. SeilerDirectorAug 2024
Wyatt R. GotbetterDirectorAug 2024